Thermo Fisher Scientific CD27 (Tumor Necrosis Factor Receptor Superfamily 7) Monoclonal Antibody (LPFS2, 4179)

Applications

Immunohistochemistry (Paraffin) (IHC (P))

• Tested Dilution: 1–2 µg/mL

Peptide Array (Array)

• Tested Dilution: Assay-dependent

Product Specifications

Product Specific Information

• Immunohistochemistry (PFA fixed): Incubate antibody for 30 min at room temperature (RT).
• Staining of formalin-fixed tissues requires heating tissue sections in 10 mM Tris with 1 mM EDTA, pH 9.0, for 45 min at 95°C, followed by cooling at RT for 20 min.

Target Information

CD27 is a 50 kDa member of the tumor necrosis factor (TNF) receptor superfamily, which includes CD40 and CD30. This family regulates cell proliferation and death. CD27 and its ligand CD70 are mainly expressed on lymphocytes, with CD27 highly expressed upon antigen receptor ligation. CD70 expression requires co-stimulatory or pro-inflammatory signals.

CD27 exists as a disulfide-linked homodimer on mature thymocytes, peripheral blood T cells, and some B cells. Activation of T cells via the TCR-CD3 complex increases CD27 expression and leads to the release of soluble CD27 (sCD27), a 28–32 kDa form detectable in plasma, urine, or spinal fluid. Soluble CD27 serves as a prognostic marker for acute and chronic B cell malignancies.

RgpA, a cysteine proteinase, can degrade CD27 and counteract CD27/CD70-mediated T cell activation. CD27-binding protein (SIVA), a proapoptotic protein, binds to CD27 and plays a role in apoptosis induced by this receptor. Diseases associated with CD27 dysfunction include Lymphoproliferative Syndrome 2 and Autosomal Recessive Lymphoproliferative Syndrome.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.